By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Ocular Research of Boston, Inc. v. Allergan
2:07-cv-00385; filed August 31, 2007 in the Eastern District of Texas
Infringement of U.S. Patent No. 5,578,586 ("Dry eye treatment process and solution," issued November 26, 1996) based on defendants' manufacture and sale of products, and by undertaking processes, embodying the patented inventions. View the complaint here.
Human Genome Sciences Inc. v. Amgen Inc. et al
1:07-cv-00526; filed August 30, 2007 in the District Court of Delaware
Review of the decision of the Board of Patent Appeals and Interferences awarding priority of invention to Immunex (now Amgen) in the interference between U.S. Patent Application 10/005,842 ("Death Domain Containing Receptor 5"), assigned to Human Genome Sciences, and U.S. Patent No. 6,642,358 ("Receptor That Binds TRAIL," issued November 4, 2003), assigned to Immunex. View the complaint here.
Sandoz, Inc. v. Eli Lilly and Company
2:07-cv-04100; filed August 27, 2007 in the District Court of New Jersey
Declaratory judgment of non-infringement and invalidity of U.S. Patent No. 5,658,590 ("Treatment of Attention-Deficit/Hyperactivity Disorder," issued August 19, 1997) in conjunction with Sandoz's filing of an ANDA to manufacture a generic version of Lilly's Strattera® (atomoxetine hydrochloride, used to treat attention-deficit/hyperactivity disorder). View the complaint here.
Celgene Corporation v. Barr Laboratories, Inc. et al.
2:07-cv-04050; filed August 23, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,230,012 ("Pharmaceutical Compositions and Dosage Forms of Thalidomide," issued June 12, 2007) following an amendment of Barr's ANDA to manufacture a generic version of Celgene's Thalomid® (thalidomide, used to treat erythema nodosum leprosum and multiple myeloma) to include a paragraph IV certification of the '012 patent. View the complaint here.
Comments